⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
10,657
Total Claims
$7.3M
Drug Cost
1,310
Beneficiaries
$5,557
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+41%
Cost per patient vs peers
$5,557 vs $3,933 avg
+21%
Brand preference vs peers
61.7% vs 51.2% avg
Brand vs Generic
38% generic
Brand: 6,043 claims · $7.0M
Generic: 3,754 claims · $88K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Asfotase Alfa | 12 | $1.8M |
| Semaglutide | 572 | $760K |
| Dulaglutide | 443 | $644K |
| Insulin Aspart | 387 | $384K |
| Empagliflozin | 279 | $270K |
| Insulin Glargine,hum.Rec.Anlog | 340 | $262K |
| Tirzepatide | 204 | $261K |
| Insulin Lispro | 177 | $199K |
| Insulin Regular, Human | 115 | $192K |
| Insulin Degludec | 279 | $180K |
| Insulin Aspart | 151 | $161K |
| Insulin Degludec | 143 | $150K |
| Lanreotide Acetate | 14 | $147K |
| Insulin Lispro | 111 | $139K |
| Insulin Glargine,hum.Rec.Anlog | 184 | $106K |
Prescribing Profile
Patient Profile
68
Avg Age
64%
Female
1.92
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About